Public record
Anastrozole: the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Medicare Part D
Medicare Part D spending on anastrozole
Medicare Part D spending on anastrozole products was $35.6M in 2024 across 1,704,262 claims, compared with $48.1M in 2023 (-25.9%). Average spending per claim was $20.90, before rebates.
| Measure | Value | Note |
|---|---|---|
| Total spending, 2024 | $35.6M | |
| Total spending, 2023 | $48.1M | |
| Change in spending, 2023 to 2024 | -25.9% | |
| Claims (prescription fills), 2024 | 1,704,262 | |
| Average spending per claim, 2024 | $20.90 | |
| Anastrozole: spending, 2024 | $32.1M | 1,702,914 claims |
| Arimidex: spending, 2024 | $3.5M | 1,348 claims |
How this was calculated
Summed total spending and claims over every brand and generic row with this generic name in the CMS file, using the Overall manufacturer rows. Combination products excluded. Average per claim is spending divided by claims.
Every single-ingredient anastrozole product in Part D (Anastrozole, Arimidex), 2024.
Gross drug cost before manufacturer rebates, so net cost is lower. Part D excludes some uses by law (for example erectile dysfunction, weight loss and hair growth), so claims reflect covered uses only. Compounded products are not included.